Tibor Markus Brunt1, Amanda Marie Atkinson2, Thomas Nefau3, Magali Martinez3, Emmanuel Lahaie3, Artur Malzcewski4, Martin Pazitny5, Vendula Belackova5, Simon D Brandt6. 1. Drug Information and Monitoring System (DIMS), Netherlands Institute of Mental Health and Addiction (Trimbos Institute), Utrecht, The Netherlands. Electronic address: tbrunt@trimbos.nl. 2. Centre for Public Health, Liverpool John Moores University, Liverpool, UK. 3. Observatoire Français des Drogues et des Toxicomanies (OFDT), Paris, France. 4. National Bureau for Drug Prevention, Warsaw, Poland. 5. Clinic of Addictology, Department of Psychiatry, Charles University, Prague. 6. School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.
Abstract
BACKGROUND: New psychoactive substances (NPS) are on offer worldwide online, in order to shed light on the purity and price of these substances in the European Union, a research collaboration was set up involving France, United Kingdom (UK), the Netherlands, Czech Republic and Poland. METHODS: Per country, around 10 different NPS were test purchased from different webshops. Then, chemical analysis of NPS was done with according reference standards to identify and quantify the contents. RESULTS: In contrast to what is generally advertised on the webshops (>99%), purity varied considerably per test purchased NPS. Several NPS were mislabelled, some containing chemical analogues (e.g. 25B/C-NBOMe instead of 25I-NBOMe, pentedrone instead of 3,4-DMMC). But in some cases NPS differed substantially from what was advertised (e.g. pentedrone instead of AMT or 3-FMC instead of 5-MeO-DALT). Per gram, purity-adjusted prices of cathinones differed substantially between three countries of test purchase, with Poland being the least expensive. Synthetic cannabinoids were relatively the most expensive in the Czech Republic and least expensive in the UK. CONCLUSION: The current findings provides a snapshot of the price and chemical contents of NPS products purchased by different countries and in different webshops. There is a potential danger of mislabelling of NPS. The great variety in price and purity of the delivered products might be the result of the market dynamics of supply and demand and the role of law enforcement in different European countries.
BACKGROUND: New psychoactive substances (NPS) are on offer worldwide online, in order to shed light on the purity and price of these substances in the European Union, a research collaboration was set up involving France, United Kingdom (UK), the Netherlands, Czech Republic and Poland. METHODS: Per country, around 10 different NPS were test purchased from different webshops. Then, chemical analysis of NPS was done with according reference standards to identify and quantify the contents. RESULTS: In contrast to what is generally advertised on the webshops (>99%), purity varied considerably per test purchased NPS. Several NPS were mislabelled, some containing chemical analogues (e.g. 25B/C-NBOMe instead of 25I-NBOMe, pentedrone instead of 3,4-DMMC). But in some cases NPS differed substantially from what was advertised (e.g. pentedrone instead of AMT or 3-FMC instead of 5-MeO-DALT). Per gram, purity-adjusted prices of cathinones differed substantially between three countries of test purchase, with Poland being the least expensive. Synthetic cannabinoids were relatively the most expensive in the Czech Republic and least expensive in the UK. CONCLUSION: The current findings provides a snapshot of the price and chemical contents of NPS products purchased by different countries and in different webshops. There is a potential danger of mislabelling of NPS. The great variety in price and purity of the delivered products might be the result of the market dynamics of supply and demand and the role of law enforcement in different European countries.
Authors: Landon M Klein; Nicholas V Cozzi; Paul F Daley; Simon D Brandt; Adam L Halberstadt Journal: Neuropharmacology Date: 2018-02-27 Impact factor: 5.250
Authors: Mehrak Javadi-Paydar; Jacques D Nguyen; Sophia A Vandewater; Tobin J Dickerson; Michael A Taffe Journal: Neuropharmacology Date: 2017-09-04 Impact factor: 5.250
Authors: Chicora F Oliver; Joseph J Palamar; Alberto Salomone; Steven J Simmons; Helene L Philogene-Khalid; Nick Stokes-McCloskey; Scott M Rawls Journal: Psychopharmacology (Berl) Date: 2018-10-18 Impact factor: 4.530